Publications by authors named "Bettina HanSSen"
Article Synopsis
- Patients with erythropoietic protoporphyria (EPP) often experience painful photosensitivity and have a high prevalence of vitamin D deficiency and osteoporosis, even after starting treatment with the drug afamelanotide, which has been available since 2016.
- A study involving 230 EPP patients analyzed vitamin D levels from 2005 to 2021, comparing those who received different treatments, including afamelanotide and cholecalciferol (vitamin D3).
- Results indicated that while afamelanotide alone did not significantly increase vitamin D levels, cholecalciferol and combined therapy with both treatments did lead to significant improvements, highlighting the importance of vitamin D supplementation for these patients.
Purpose: To compare a self-etch and a two-step etch-and-rinse adhesive in terms of internal and marginal composite-tooth bond failure separately on enamel and dentin/cement at 36-48 months after restoration placement using optical coherence tomography (OCT).
Materials And Methods: Twenty-seven patients with two or three class V composite restorations of noncarious cervical lesions 36-48 months after placement were included. The one-step self-etch adhesive Futurabond M ([Voco] group SE, n = 25) and the two-step etch-and-rinse adhesive Solobond M ([Voco] group ER, n = 20) combined with the nanohybrid composite Amaris (Voco) were evaluated.
Background: Although it is well recognized that fatigue is an important problem in many of the quiescent inflammatory bowel disease (IBD) patients, it is unknown whether the immune status is different in fatigued versus non-fatigued patients. In this study, we contrasted various characteristics of the immune system in fatigued against non-fatigued patients with IBD in clinical remission.
Patients And Methods: Patients with IBD in clinical remission were phenotyped according to the Montreal classification, and the checklist individual strength-fatigue (CIS-fatigue) was used to assess fatigue (CIS-fatigue ≥ 35).